ReviewJournal of gastrointestinal cancer2011
Polycomb and the emerging epigenetics of pancreatic cancer.
Review in Journal of gastrointestinal cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Unraveling the molecular landscape of pancreatic cancer: a systems biology approach to identify therapeutic targets.Discover oncology · 2025Article
- Deoxyribonucleic acid methylation driven aberrations in pancreatic cancer-related pathways.World journal of gastrointestinal oncology · 2023Review
- Intrinsically disordered chromatin protein NUPR1 binds to the C-terminal region of Polycomb RING1B.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?Gut · 2017Review
- EZH2 in Bladder Cancer, a Promising Therapeutic Target.International journal of molecular sciences · 2015Review
- YY1 regulates melanoma tumorigenesis through a miR-9 ~ RYBP axis.Journal of experimental & clinical cancer research : CR · 2015Article
- Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects.World journal of gastroenterology · 2014Review
- Potential epigenetic mechanism(s) associated with the persistence of psychoneurological symptoms in women receiving chemotherapy for breast cancer: a hypothesis.Biological research for nursing · 2014Article
- Insights into the epigenetic mechanisms controlling pancreatic carcinogenesis.Cancer letters · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
introductionThe revolution of epigenetics has revitalized cancer research, shifting focus away from somatic mutation toward a more holistic perspective involving the dynamic states of chromatin. Disruption of chromatin organization can directly and indirectly precipitate genomic instability and transformation. DISCUSSION: One group of epigenetic mediators, the Polycomb group (PcG) proteins, establishes heritable gene repression through methylation of histone tails. Although classically considered regulators of development and cellular differentiation, PcG proteins engage in a variety of neoplastic processes, including cellular proliferation and invasion. Due to their multifaceted potential, PcG proteins rest at the intersection of transcriptional memory and malignancy. Expression levels of PcG proteins hold enormous diagnostic and prognostic value in breast, prostate, and more recently, gastrointestinal cancers.
conclusionIn this review, we briefly summarize the function of PcG proteins and report the latest developments in understanding their role in pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.